Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
Posted on: Wednesday, 6 May 2009, 06:30 CDT
The ongoing phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects are documented whenever possible.
"We are very pleased that high doses of AXL1717 could be administered to patients without significant side effects during the single-day treatments.", says Johan Harmenberg, CEO of Axelar AB. "Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may be a new and well-tolerated treatment alternative for cancer patients in the future."
The IGF-1 receptor is a promising target for the treatment of cancer, since the receptor is crucial for the survival and growth of malignant cells. In contrast, the IGF-1 receptor is not absolutely necessary for growth of normal cells.
AXL1717 is a small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data show an extraordinary anti-tumor efficacy in animal models, including apparent complete tumor regression, for a wide range of human cancers such as breast cancer, prostate cancer, malignant melanoma, multiple myeloma, glioblastoma and sarcoma. AXL1717, orally administered, is being developed as a new type of anti-cancer drug.
About Cancer, the IGF-1 receptor and AXL1717
Globally more than 12 million people are diagnosed with cancer every year. Cancer causes the death of about 8 million people per year. Although a number of cancer drugs have successfully been launched over the last decade, many cancers still lack an effective therapy. This, together with the fact that many treatments result in severe side effects, highlights the strong medical need for new and alternative anti-cancer therapies.
About Axelar AB
Axelar AB is a Swedish biotech company founded in 2003 and based on
research performed at the
For more information, please contact:
Johan Harmenberg, MD, PhD (CEO Axelar AB)
Telephone: +46-705-14-54-53 or visit http://www.axelar.se
SOURCE Karolinska Development AB
Source: PR Newswire
Related Articles
- Depression In Older Cancer Patients Can Be Effectively Treated With Collaborative Approach
- COPAXONE(R) Demonstrated Protective Effect in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results*
- Quality-of-Life Determinants in Patients With Clinically Stable Bronchiectasis*
- Plasma Soluble Vascular Endothelial Growth Factor Receptor-1 Concentration is Elevated Prior to the Clinical Diagnosis of Pre- Eclampsia
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
 |
 |
User Comments (0)
RSS Feeds